Walgreens and the Cardiovascular Research Foundation Unite to Improve Recognition and Diagnosis of Valvular Heart Disease for Older Americans
18 Outubro 2023 - 7:00AM
Business Wire
This collaboration will bolster patient
recruitment efforts to increase diversity and access in the
PREVUE-VALVE study
Walgreens and the Cardiovascular Research Foundation (CRF) today
announced a collaboration to drive forward the PREVUE-VALVE study,
a groundbreaking population-based clinical trial that aims to
quantify the prevalence of valvular heart disease (VHD) among older
Americans and pave the way for the development of new therapies and
tools for VHD detection and diagnosis.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231018497392/en/
Walgreens is collaborating with the
Cardiovascular Research Foundation (CRF) to advance the
PREVUE-VALVE clinical trial for valvular heart disease treatments.
Walgreens goal is to make clinical trials accessible to all, and
its partnership with CRF combines the expertise and resources
needed to transform cardiovascular research, laying the groundwork
for the development of innovative treatments. (Photo: Business
Wire)
Walgreens aims to leverage its national presence, strong
community relationships and data-driven clinical trials solutions
to help identify and reach potential study participants.
“The aging population has led to a surge in the incidence and
prevalence of valvular heart disease in the United States.
Unfortunately, many patients with valvular heart disease remain
untreated or receive treatment later than recommended due to
various barriers. At the Cardiovascular Research Foundation, we
believe efficient clinical trials are essential for arming us with
insights to effectively tackle this critical health challenge,”
said David J. Cohen, MD, MSc, Director of Clinical and Outcomes
Research at CRF. “Partnering with Walgreens will help us engage a
broader and more representative patient population for enrollment
in the PREVUE-VALVE study so that we can improve our ability to
diagnose valvular heart disease before the onset of irreversible
cardiac damage, which will allow for more timely treatment and
ultimately, better health outcomes, for our patients.”
Walgreens will provide patient recruitment services to support
this study, which seeks to define the prevalence of VHD in older
Americans and to ensure representative access and enrollment. To
enhance patient convenience and engagement, participants will have
all study procedures performed in the comfort of their homes. By
leveraging longitudinal pharmacy and social determinants of health
insights and proprietary automated recruitment selection software,
Walgreens looks forward to reaching eligible patients for
enrollment at the right time to deliver the right message and help
orchestrate their participation seamlessly.
Historically, estimates of the prevalence of VHD in the United
States have been derived from homogeneous populations with minimal
diversity—particularly with respect to race and ethnicity.
Furthermore, the older population, where VHD is more prevalent, has
been disproportionately excluded from clinical trials. By enrolling
a population representative of the U.S. as a whole, the
PREVUE-VALVE study is a crucial step toward developing testing and
treatments that address the needs of the most affected
patients.
“We know that older adults are vastly underrepresented in
clinical trials and research despite being disproportionately
impacted by many diseases,” said Ramita Tandon, chief clinical
trials officer, Walgreens. “Walgreens is proud to leverage our
expertise and capabilities in inclusive clinical trial recruitment
in partnership with the Cardiovascular Research Foundation and
other high-caliber collaborators to improve cardiovascular research
for a population with significant unmet needs.”
In a similar Phase 3 cardiovascular study, Walgreens exceeded
its recruitment within weeks. Real-world insights enabled Walgreens
to tap into historically underrepresented populations, resulting in
a significant increase in Black/African American (17%) and
Hispanic/Latino (19%) participation in the clinical trial, compared
to nationwide 2020 averages of clinical trial participation of 8%
and 11% respectively.
The PREVUE-VALVE study is currently underway, with topline
results expected in 2025, making a significant step forward in the
fight against valvular heart disease.
About Walgreens
Walgreens (www.walgreens.com) is included in the U.S. Retail
Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance,
Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail
leader with a 170-year heritage of caring for communities. WBA’s
purpose is to create more joyful lives through better health.
Operating nearly 9,000 retail locations across America, Puerto Rico
and the U.S. Virgin Islands, Walgreens is proud to be a
neighborhood health destination serving nearly 10 million customers
each day. Walgreens pharmacists play a critical role in the U.S.
healthcare system by providing a wide range of pharmacy and
healthcare services, including those that drive equitable access to
care for the nation’s medically underserved populations. To best
meet the needs of customers and patients, Walgreens offers a true
omnichannel experience, with fully integrated physical and digital
platforms supported by the latest technology to deliver
high-quality products and services in communities nationwide.
About the Cardiovascular Research Foundation
The Cardiovascular Research Foundation (CRF) is one of the
world’s leading nonprofit organizations specializing in
interventional cardiology innovation, research, and education. CRF
is dedicated to helping doctors improve survival and quality of
life for people suffering from heart and vascular disease. For over
30 years, CRF has helped accelerate medical breakthroughs and
educated doctors on the latest treatments for heart disease. CRF’s
centers of excellence include the CRF Skirball Center for
Innovation, CRF Clinical Trials Center, CRF Center for Education,
CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart
Team. For more information, visit www.crf.org.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231018497392/en/
Walgreens Jonathon Hosea media@walgreens.com
Cardiovascular Research Foundation (CRF) Judy Romero
press@crf.org
Walgreens Boots Alliance (NASDAQ:WBA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Walgreens Boots Alliance (NASDAQ:WBA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024